Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2018

Zadra G, Loda M. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities. Cold Spring Harb Perspect Med. 2018;8(10).

Zhai Y, Song W, Zeng J, Zhao Z, Cao Z. A 31-Year-Old Woman with Consecutive Pregnancy Losses. Clin Chem. 2018;64(5):777-780.

Al-Tamari HM, Dabral S, Schmall A, Sarvari P, Ruppert C, Paik J, et al. FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. EMBO Mol Med. 2018;10(2):276-293.

Nayar R, Barkan GA, Benedict C, Booth C, Chhieng DC, Mody D, et al. Laboratory management curriculum for cytopathology subspecialty training. J Am Soc Cytopathol. 2018;7(2):61-78.

Viswanathan K, Cheng E, Linver MN, Feddersen R, Hoda S. Bilateral Multiple Mammary Myofibroblastomas in an Adult Male. Int J Surg Pathol. 2018;26(3):242-244.

Mottahedeh J, Haffner MC, Grogan TR, Hashimoto T, Crowell PD, Beltran H, et al. CD38 is methylated in prostate cancer and regulates extracellular NAD. Cancer Metab. 2018;6:13.

Soshnev AA, Josefowicz SZ, C Allis D. Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome. Mol Cell. 2018;69(3):533.

Shiue K, Cerra-Franco A, Shapiro R, Estabrook N, Mannina EM, Deig CR, et al. Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy. J Thorac Oncol. 2018;13(10):1549-1559.

Schwartz Z, Bowe RB, Coleman M, Magro CM. Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity. Ann Diagn Pathol. 2018;37:57-61.

Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, et al. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Sci Rep. 2018;8(1):7189.